Search

Sheela Jitendra Huff

Examiner (ID: 29, Phone: (571)272-0834 , Office: P/1643 )

Most Active Art Unit
1643
Art Unit(s)
1642, 1806, 1643, RD00, 1811
Total Applications
2210
Issued Applications
1470
Pending Applications
183
Abandoned Applications
574

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18182322 [patent_doc_number] => 20230043051 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-09 [patent_title] => ADENO-ASSOCIATED VIRUS VECTORS BASED GENE THERAPY FOR HEREDITARY ANGIOEDEMA [patent_app_type] => utility [patent_app_number] => 17/771275 [patent_app_country] => US [patent_app_date] => 2020-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11394 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17771275 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/771275
ADENO-ASSOCIATED VIRUS VECTORS BASED GENE THERAPY FOR HEREDITARY ANGIOEDEMA Oct 22, 2020 Abandoned
Array ( [id] => 18565700 [patent_doc_number] => 20230256027 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => Use of Liver Progenitor or Stem Cells, Lysates Thereof, and/or Conditioned Medium in Disorders Characterized by Vascular Hyperpermeability [patent_app_type] => utility [patent_app_number] => 17/766527 [patent_app_country] => US [patent_app_date] => 2020-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766527 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/766527
Use of Liver Progenitor or Stem Cells, Lysates Thereof, and/or Conditioned Medium in Disorders Characterized by Vascular Hyperpermeability Oct 7, 2020 Abandoned
Array ( [id] => 17913512 [patent_doc_number] => 20220315907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-06 [patent_title] => SPLIT CRISPR NUCLEASE TETHERING SYSTEM [patent_app_type] => utility [patent_app_number] => 17/639022 [patent_app_country] => US [patent_app_date] => 2020-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27103 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17639022 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/639022
SPLIT CRISPR NUCLEASE TETHERING SYSTEM Sep 30, 2020 Abandoned
Array ( [id] => 17830452 [patent_doc_number] => 20220267756 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING GENOMIC COMPLEX INTEGRITY INDEX [patent_app_type] => utility [patent_app_number] => 17/754050 [patent_app_country] => US [patent_app_date] => 2020-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17754050 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/754050
COMPOSITIONS AND METHODS FOR MODULATING GENOMIC COMPLEX INTEGRITY INDEX Sep 21, 2020 Pending
Array ( [id] => 18019141 [patent_doc_number] => 20220370640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => GENE THERAPY EXPRESSION SYSTEM ALLEVIATING CARDIAC TOXICITY OF FKRP [patent_app_type] => utility [patent_app_number] => 17/753768 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753768 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/753768
GENE THERAPY EXPRESSION SYSTEM ALLEVIATING CARDIAC TOXICITY OF FKRP Sep 17, 2020 Pending
Array ( [id] => 18020944 [patent_doc_number] => 20220372443 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => LBM, CPC, OPC, PRODUCTION AND QUALITY CONTROL METHODS THEREFOR, KIT, GRAFT MATERIAL, AND DISEASE MODEL [patent_app_type] => utility [patent_app_number] => 17/761518 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17664 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17761518 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/761518
LBM, CPC, OPC, PRODUCTION AND QUALITY CONTROL METHODS THEREFOR, KIT, GRAFT MATERIAL, AND DISEASE MODEL Sep 17, 2020 Pending
Array ( [id] => 18019141 [patent_doc_number] => 20220370640 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => GENE THERAPY EXPRESSION SYSTEM ALLEVIATING CARDIAC TOXICITY OF FKRP [patent_app_type] => utility [patent_app_number] => 17/753768 [patent_app_country] => US [patent_app_date] => 2020-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14536 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17753768 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/753768
GENE THERAPY EXPRESSION SYSTEM ALLEVIATING CARDIAC TOXICITY OF FKRP Sep 17, 2020 Pending
Array ( [id] => 18021022 [patent_doc_number] => 20220372521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-24 [patent_title] => RNA-GUIDED DNA INTEGRATION AND MODIFICATION [patent_app_type] => utility [patent_app_number] => 17/634759 [patent_app_country] => US [patent_app_date] => 2020-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 1 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634759 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/634759
RNA-GUIDED DNA INTEGRATION AND MODIFICATION Aug 13, 2020 Abandoned
Array ( [id] => 18752502 [patent_doc_number] => 20230355759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 [patent_app_type] => utility [patent_app_number] => 17/597968 [patent_app_country] => US [patent_app_date] => 2020-07-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43193 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17597968 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/597968
POPULATIONS OF NATURAL KILLER CELLS COMPRISING A CLEAVAGE RESISTANT CD16 Jul 30, 2020 Pending
Array ( [id] => 18077720 [patent_doc_number] => 20220403332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => SELF-ORGANIZING NEURAL ECTODERMAL LINEAGE CELLULAR STRUCTURES, AND COMPOSITIONS AND METHODS RELATING THERETO [patent_app_type] => utility [patent_app_number] => 17/621328 [patent_app_country] => US [patent_app_date] => 2020-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21683 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 42 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17621328 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/621328
SELF-ORGANIZING NEURAL ECTODERMAL LINEAGE CELLULAR STRUCTURES, AND COMPOSITIONS AND METHODS RELATING THERETO Jun 21, 2020 Pending
Array ( [id] => 17720769 [patent_doc_number] => 20220213489 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => CD33 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF CD33 POSITIVE MALIGNANCIES [patent_app_type] => utility [patent_app_number] => 17/614233 [patent_app_country] => US [patent_app_date] => 2020-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5790 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614233 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/614233
CD33 targeted chimeric antigen receptor modified T cells for treatment of CD33 positive malignancies May 31, 2020 Issued
Array ( [id] => 17720714 [patent_doc_number] => 20220213434 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => MODIFIED PLURIPOTENT CELLS [patent_app_type] => utility [patent_app_number] => 17/607841 [patent_app_country] => US [patent_app_date] => 2020-05-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22208 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -116 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17607841 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/607841
MODIFIED PLURIPOTENT CELLS May 8, 2020 Pending
Array ( [id] => 17776876 [patent_doc_number] => 20220243225 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS [patent_app_type] => utility [patent_app_number] => 17/606635 [patent_app_country] => US [patent_app_date] => 2020-04-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67011 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17606635 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/606635
SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS Apr 28, 2020 Abandoned
Array ( [id] => 16628969 [patent_doc_number] => 20210047622 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-18 [patent_title] => METHOD FOR OBTAINING AN ANIMAL MODEL FROM CONDITIONALLY REPROGRAMMED CELLS AND USE OF THE ANIMAL MODEL FOR SCREEING ANTI-TUMOR DRUGS [patent_app_type] => utility [patent_app_number] => 17/046981 [patent_app_country] => US [patent_app_date] => 2019-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7136 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046981 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/046981
METHOD FOR OBTAINING AN ANIMAL MODEL FROM CONDITIONALLY REPROGRAMMED CELLS AND USE OF THE ANIMAL MODEL FOR SCREEING ANTI-TUMOR DRUGS Mar 18, 2019 Pending
Menu